The rare DAT coding variant Val559 perturbs da neuron function, changes behavior, and alters in vivo responses to psychostimulants

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 44, 2014, Pages E4779-E4788

  Mergy, Marc A ^a   Gowrishankar, Raajaram ^a   Gresch, Paul J ^a   Gantz, Stephanie C ^b   Williams, John ^b   Davis, Gwynne L ^a   Wheeler, C Austin ^a   Stanwood, Gregg D ^a   Hahn, Maureen K ^a,c   Blakely, Ry D ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopamine; Mouse; Polymorphism; Transgenic; Transporter

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; PSYCHOSTIMULANT AGENT; CENTRAL STIMULANT AGENT; SLC6A3 PROTEIN, HUMAN; SLC6A3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CASE REPORT; CODING; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; MALE; MENTAL DISEASE; MOUSE; NERVE CELL; NONHUMAN; RECOGNITION; SIBLING; TREATMENT RESPONSE; AMINO ACID SUBSTITUTION; ANIMAL; ANIMAL BEHAVIOR; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY;

MUS;

AMINO ACID SUBSTITUTION; AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MICE; MUTATION, MISSENSE; RECEPTORS, DOPAMINE D2;

EID: 84914695673     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1417294111     Document Type: Article

References (100)

1. Bannon MJ (2005) The dopamine transporter: Role in neurotoxicity and human disease. Toxicol Appl Pharmacol 204(3):355-360.
2. Giros B, Caron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14(2):43-49.
3. Palmiter RD (2008) Dopamine signaling in the dorsal striatum is essential for motivated behaviors: Lessons from dopamine-deficient mice. Ann N Y Acad Sci 1129: 35-46.
4. Temlett JA (1996) Parkinson's disease: Biology and aetiology. Curr Opin Neurol 9(4): 303-307.
5. Hayden EP, Nurnberger JI, Jr (2006) Molecular genetics of bipolar disorder. Genes Brain Behav 5(1):85-95.
6. Kalivas PW, Volkow ND (2005) The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 162(8):1403-1413.
7. Faraone SV, Biederman J (1998) Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 44(10):951-958.
8. Mazei-Robison MS, Blakely RD (2005) Expression studies of naturally occurring human dopamine transporter variants identifies a novel state of transporter inactivation associated with Val382Ala. Neuropharmacology 49(6):737-749.
9. Gowrishankar R, Hahn MK, Blakely RD (2014) Good riddance to dopamine: Roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders. Neurochem Int 73:42-48.
10. Vaughan RA, Foster JD (2013) Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 34(9):489-496.
11. Sulzer D, Galli A (2003) Dopamine transport currents are promoted from curiosity to physiology. Trends Neurosci 26(4):173-176.
12. Fog JU, et al. (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51(4): 417-429.
13. Bowton E, et al. (2010) Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 30(17):6048-6057.
14. Binda F, et al. (2008) Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol Pharmacol 74(4):1101-1108.
15. Gnegy ME, et al. (2004) Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol Pharmacol 66(1):137-143.
16. Pizzo AB, et al. (2014) Amphetamine-induced behavior requires CaMKII-dependent dopamine transporter phosphorylation. Mol Psychiatry 19(3):279-281.
17. Cremona ML, et al. (2011) Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nat Neurosci 14(4):469-477.
18. Johnson LA, Guptaroy B, Lund D, Shamban S, Gnegy ME (2005) Regulation of am-phetamine- stimulated dopamine efflux by protein kinase C beta. J Biol Chem 280(12):10914-10919.
19. Kantor L, Gnegy ME (1998) Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 284(2):592-598.
20. Hamilton PJ, et al. (2014) PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. Nat Chem Biol 10(7):582-589.
21. Cervinski MA, Foster JD, Vaughan RA (2005) Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J Biol Chem 280(49):40442-40449.
22. Khoshbouei H, et al. (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2(3):E78.
23. Pizzo AB, et al. (2013) The membrane raft protein Flotillin-1 is essential in dopamine neurons for amphetamine-induced behavior in Drosophila. Mol Psychiatry 18(7): 824-833.
24. Spencer TJ, et al. (2013) Effect of psychostimulants on brain structure and function in ADHD: A qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J Clin Psychiatry 74(9):902-917.
25. Arnsten AF (2006) Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31(11):2376-2383.
26. Bellgrove MA, Hawi Z, Kirley A, Gill M, Robertson IH (2005) Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: Sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype. Neuropsychologia 43(13):1847-1857.
27. Joober R, et al. (2007) Dopamine transporter 3? -UTR VNTR genotype and ADHD: A pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 32(6):1370-1376.
28. Stein MA, et al. (2005) Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30(7):1374-1382.
29. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379(6566):606-612.
30. Gainetdinov RR, et al. (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283(5400):397-401.
31. van Enkhuizen J, et al. (July 9, 2014) Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology, 10.1038/npp.2014.170.
32. van Enkhuizen J, Geyer MA, Halberstadt AL, Zhuang X, Young JW (2014) Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord 155:247-254.
33. Salahpour A, Medvedev IO, Beaulieu JM, Gainetdinov RR, Caron MG (2007) Local knockdown of genes in the brain using small interfering RNA: A phenotypic comparison with knockout animals. Biol Psychiatry 61(1):65-69.
34. Cagniard B, Balsam PD, Brunner D, Zhuang X (2006) Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 31(7):1362-1370.
35. Willner P (1986) Validation criteria for animal models of human mental disorders: Learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 10(6):677-690.
36. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M (1991) Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30(5): 762-767.
37. Elia J, Ambrosini PJ, Rapoport JL (1999) Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 340(10):780-788.
38. Findling RL (1996) Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series. J Child Adolesc Psychopharmacol 6(3):165-175.
39. Volkow ND, Gatley SJ, Fowler JS, Wang GJ, Swanson J (2000) Serotonin and the therapeutic effects of ritalin. Science 288(5463):11.
40. Kurian MA, et al. (2011) Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: An observational cohort and experimental study. Lancet Neurol 10(1):54-62.
41. Ng J, et al. (2014) Dopamine transporter deficiency syndrome: Phenotypic spectrum from infancy to adulthood. Brain 137(Pt 4):1107-1119.
42. Nigg J, Nikolas M, Burt SA (2010) Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 49(9):863-873.
43. Wermter AK, et al. (2010) From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. Eur Child Adolesc Psychiatry 19(3):199-210.
44. Boerio D, Kalmar B, Greensmith L, Bostock H (2010) Excitability properties of mouse motor axons in the mutant SOD1(G93A) model of amyotrophic lateral sclerosis. Muscle Nerve 41(6):774-784.
45. Hassouna R, et al. (2012) A natural variant of obestatin, Q90L, inhibits ghrelin's action on food intake and GH secretion and targets NPY and GHRH neurons in mice. PLoS ONE 7(12):e51135.
46. Veenstra-VanderWeele J, et al. (2012) Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc Natl Acad Sci USA 109(14):5469-5474.
47. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD (2005) Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49(6):724-736.
48. Grünhage F, et al. (2000) Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol Psychiatry 5(3): 275-282.
49. Bowton E, et al. SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Transl Psychiatr, 10.1038/ tp.2014.90.
50. Gadow KD, Roohi J, DeVincent CJ, Hatchwell E (2008) Association of ADHD, tics, and anxiety with dopamine transporter (DAT1) genotype in autism spectrum disorder. J Child Psychol Psychiatry 49(12):1331-1338.
51. Nakamura K, et al. (2010) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 67(1):59-68.
52. Nguyen M, et al. (2014) Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD). Neurochem Int 66:15-26.
53. Farook MF, et al. (2012) Altered serotonin, dopamine and norepinepherine levels in 15q duplication and Angelman syndrome mouse models. PLoS ONE 7(8):e43030.
54. Murray ML, et al. (2014) Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology (Berl) 231(6):1011-1021.
55. Dichter GS, Richey JA, Rittenberg AM, Sabatino A, Bodfish JW (2012) Reward circuitry function in autism during face anticipation and outcomes. J Autism Dev Disord 42(2):147-160.
56. Scott-Van Zeeland AA, Dapretto M, Ghahremani DG, Poldrack RA, Bookheimer SY (2010) Reward processing in autism. Autism Res 3(2):53-67.
57. Abrams DA, et al. (2013) Underconnectivity between voice-selective cortex and reward circuitry in children with autism. Proc Natl Acad Sci USA 110(29):12060-12065.
58. Mazei-Robison MS, et al. (2008) Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci 28(28):7040-7046.
59. Mergy MA, et al. (2014) Genetic targeting of the amphetamine and methylpheni-date- sensitive dopamine transporter: On the path to an animal model of attentiondeficit hyperactivity disorder. Neurochem Int 73:56-70.
60. Ford CP, Gantz SC, Phillips PE, Williams JT (2010) Control of extracellular dopamine at dendrite and axon terminals. J Neurosci 30(20):6975-6983.
61. Beckstead MJ, Grandy DK, Wickman K, Williams JT (2004) Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons. Neuron 42(6):939-946.
62. Gantz SC, Bunzow JR, Williams JT (2013) Spontaneous inhibitory synaptic currents mediated by a G protein-coupled receptor. Neuron 78(5):807-812.
63. Branch SY, Beckstead MJ (2012) Methamphetamine produces bidirectional, con-centration- dependent effects on dopamine neuron excitability and dopaminemediated synaptic currents. J Neurophysiol 108(3):802-809.
64. Spielewoy C, et al. (2000) Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol 11(3-4): 279-290.
65. Gainetdinov RR, Caron MG (2000) An animal model of attention deficit hyperactivity disorder. Mol Med Today 6(1):43-44.
66. Zhuang X, et al. (2001) Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 98(4):1982-1987.
67. rd (2002) Young adult outcome of children with "situational" hyperactivity: A prospective, controlled follow-up study. J Abnorm Child Psychol 30(2):191-198.
68. Whalen CK, et al. (2006) An electronic diary study of contextual triggers and ADHD: Get ready, get set, get mad. J Am Acad Child Adolesc Psychiatry 45(2):166-174.
69. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 75(6):406-433.
70. O'Neill MF, Shaw G (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl) 145(3):237-250.
71. Hall DA, Powers JP, Gulley JM (2009) Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat. Brain Res 1300:51-57.
72. Kauwe JS, Wang J, Chakraverty S, Goate AM, Henao-Martinez AF (2008) Novel presenilin 1 variant (P117A) causing Alzheimer's disease in the fourth decade of life. Neurosci Lett 438(2):257-259.
73. Quast C, et al. (2012) Rare variants in TMEM132D in a case-control sample for panic disorder. Am J Med Genet B Neuropsychiatr Genet 159B(8):896-907.
74. Takata A, et al. (2013) A population-specific uncommon variant in GRIN3A associated with schizophrenia. Biol Psychiatry 73(6):532-539.
75. Horschitz S, Hummerich R, Lau T, Rietschel M, Schloss P (2005) A dopamine transporter mutation associated with bipolar affective disorder causes inhibition of transporter cell surface expression. Mol Psychiatry 10(12):1104-1109.
76. Zech M, et al. (2014) DYT16 revisited: Exome sequencing identifies PRKRA mutations in a European dystonia family. Mov Disord, 10.1002/mds.25981.
77. Sakrikar D, et al. (2012) Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation. J Neurosci 32(16):5385-5397.
78. Leyfer OT, et al. (2006) Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. J Autism Dev Disord 36(7):849-861.
79. Kaffman A, Krystal JH (2012) New frontiers in animal research of psychiatric illness. Methods Mol Biol 829:3-30.
80. Clements CC, et al. (2014) Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry, 10.1038/mp.2014.90.
81. Siesser WB, Zhao J, Miller LR, Cheng SY, McDonald MP (2006) Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive. Genes Brain Behav 5(3):282-297.
82. Okamoto K, Aoki K (1963) Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27:282-293.
83. Kantak KM, et al. (2008) Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behav Neurosci 122(2):340-357.
84. van den Bergh FS, et al. (2006) Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol Biochem Behav 83(3):380-390.
85. van der Kooij MA, Glennon JC (2007) Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev 31(4): 597-618.
86. Leo D, Gainetdinov RR (2013) Transgenic mouse models for ADHD. Cell Tissue Res 354(1):259-271.
87. Kafkafi N, et al. (2003) Darting behavior: A quantitative movement pattern designed for discrimination and replicability in mouse locomotor behavior. Behav Brain Res 142(1-2):193-205.
88. Lodge DJ (2011) The medial prefrontal and orbitofrontal cortices differentially regulate dopamine system function. Neuropsychopharmacology 36(6):1227-1236.
89. Aron AR, Poldrack RA (2005) The cognitive neuroscience of response inhibition: Relevance for genetic research in attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11):1285-1292.
90. Barnes JJ, Dean AJ, Nandam LS, O'Connell RG, Bellgrove MA (2011) The molecular genetics of executive function: Role of monoamine system genes. Biol Psychiatry 69(12):e127-e143.
91. van den Wildenberg WP, et al. (2010) To head or to heed? Beyond the surface of selective action inhibition: A review. Front Hum Neurosci 4:222.
92. Humby T, Eddy JB, Good MA, Reichelt AC, Wilkinson LS (2013) A novel translational assay of response inhibition and impulsivity: Effects of prefrontal cortex lesions, drugs used in ADHD, and serotonin 2c receptor antagonism. Neuropsychopharmacology 38(11):2150-2159.
93. Loos M, et al. (2010) Inhibitory control and response latency differences between C57BL/6J and DBA/2J mice in a Go/No-Go and 5-choice serial reaction time task and strain-specific responsivity to amphetamine. Behav Brain Res 214(2):216-224.
94. Young JW, Kooistra K, Geyer MA (2011) Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology 36(7): 1385-1396.
95. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18(6):1979-1986.
96. Lossin C, Wang DW, Rhodes TH, Vanoye CG, George AL, Jr (2002) Molecular basis of an inherited epilepsy. Neuron 34(6):877-884.
97. Matthews E, et al. (2009) Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology 72(18):1544-1547.
98. Hastrup H, Karlin A, Javitch JA (2001) Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci USA 98(18):10055-10060.
99. Milner HE, Béliveau R, Jarvis SM (1994) The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. Biochim Biophys Acta 1190(1): 185-187.
100. Volkow ND, et al. (2009) Evaluating dopamine reward pathway in ADHD: Clinical implications. JAMA 302(10):1084-1091.